Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.50 |
| ▸ | BMP1 | P13497 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 3/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | CAPN1 | P07384 | 3/20 | 0.46 |
| ▸ | CTSL | P07711 | 4/20 | 0.45 |
| ▸ | HPGDS | O60760 | 1/20 | 0.45 |
| ▸ | ACKR3 | P25106 | 7/20 | 0.42 |
| ▸ | CTSK | P43235 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4136156 | 0.88 | TRPV4 (0.48) | TRPV4BMP1CTSSCTSBCAPN1 | |
| SCHEMBL4147519 | 0.87 | TRPV4 (0.66) | TRPV4BMP1CTSSCTSBCAPN1 | |
| SCHEMBL5434875 | 0.85 | TRPV4 (0.66) | TRPV4BMP1CTSSCTSBCAPN1 | |
| SCHEMBL4142150 | 0.84 | TRPV4 (0.51) | TRPV4BMP1CTSSCAPN1CTSL | |
| SCHEMBL4127268 | 0.81 | CTSK (0.53) | TRPV4BMP1CTSSCTSBCAPN1 | |
| SCHEMBL4142303 | 0.81 | CAPN1 (0.48) | TRPV4BMP1CTSSCAPN1CTSL | |
| SCHEMBL4139727 | 0.81 | BMP1 (0.47) | TRPV4BMP1CTSSCAPN1CTSL | |
| SCHEMBL4139891 | 0.80 | BMP1 (0.39) | TRPV4BMP1CAPN1HPGDSACKR3 | |
| SCHEMBL4135948 | 0.80 | BMP1 (0.49) | TRPV4BMP1CAPN1CTSLCTSK | |
| SCHEMBL5446412 | 0.80 | TRPV4 (0.49) | TRPV4BMP1CTSSCAPN1CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | claimed |
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
| WO-2007030761-A2 | ACYCLIC 1,4-DIAMINES AND USES THEREOF | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | TRPV4, TRPC4, TRPV1 | TRPV4 1/4885BMP1 2172/4885CTSS 3772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.